Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Announce Opdivo’s New Prices on Nov. 24
November 24, 2016
-
BUSINESS Taltz Finally Makes it to Japan Market after Pricing Flap
November 22, 2016
-
BUSINESS 3 Japan Generic Majors See Subdued Sales Rise in April-September
November 21, 2016
-
REGULATORY MHLW to Kick Off Discussions for Major Drug Pricing Overhaul by Year-End: Bureau Chief
November 18, 2016
-
REGULATORY 50% Price Cut for Opdivo OK’ed with Estimated Sales of 151.6-Plus Billion Yen
November 17, 2016
-
REGULATORY ICH Eyes Major GCP Revamp with Use of Real World Data: Osaka Confab
November 16, 2016
-
REGULATORY Opdivo’s NHI Price-Based Sales Put at Over 151 Billion Yen; 50% Cut Likely to Take Effect Feb. 1
November 15, 2016
-
TRENDS AGs Set to Break into 10 Billion Yen Territory in Japan
November 14, 2016
-
REGULATORY MHLW Panel to Discuss NSCLC Indication for Keytruda on Nov. 24
November 14, 2016
-
REGULATORY LDP Study Group on Biologics to Hold 1st Meeting on Nov. 24; Aims to Halt the Rush to Promote Biosimilars
November 11, 2016
-
BUSINESS Top 4 Wholesalers See Lower Sales in April-September If Hep C Meds Excluded
November 11, 2016
-
REGULATORY MHLW Plans 50% Price Cut for Opdivo
November 10, 2016
-
REGULATORY Chuikyo OKs Taltz, Micatrio for Listing on Nov. 18; Keytruda Takes Pass This Time
November 9, 2016
-
BUSINESS Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
November 8, 2016
-
BUSINESS MSD’s New Dual Oral Hep C Therapy to Challenge Harvoni; Effective Regardless of Resistance Mutations, Renal Impairment
November 8, 2016
-
ACADEMIA Draft Guidelines on Pneumonia Treatment Set Guides for Selecting Antibacterial Agents: Respiratory Society
November 7, 2016
-
REGULATORY PMDA Mulls Fee Raise for Drug, Device Reviews
November 4, 2016
-
REGULATORY MHLW Struggling to Set Date for Chuikyo Subcommittee Discussions on Opdivo
November 2, 2016
-
BUSINESS Strong Yen Dampens Sales of 4 Japanese Majors, but Global Brands Keep Up Momentum
November 2, 2016
-
BUSINESS Daiichi Sankyo Earnings Lower on Yen Moves; Olmesartan Suffers 21.8% Slide
November 1, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…